Page 2 - Moral Small News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 22, 2020 3:00am Drug manufacturers are looking for a more local future for production post-COVID-19. (Pixabay)(Monica Alleven/Fierce Wireless) With the COVID-19 pandemic perhaps entering its final phase as the first wave of vaccines approaches the market, one question left unanswered is the future of "onshoring" drug manufacturing—an initiative that reached fever pitch in 2019 as nationwide lockdowns and geopolitical tension cast a spotlight on the global supply chain. In 2019, congressional leaders across the aisle picked up steam on a suite of bills aimed at incentivizing and driving ...

RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies) Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site. Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and comme...

Dec 22, 2020 9:15am Big name pharmas, budding biopharmas and research institutions the world over are plugging away on the next generation of drugs and vaccines against the COVID-19 pandemic. (Bill Oxford/Getty Images) As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020—and they're looking at new formulations and delivery methods to bring vaccines and therapies to more people around the world.  Can follow-up shots ease the harsh cold chain requirements for mRNA vaccines? Could supplies be extended with a v...

Dec 22, 2020 9:00am Drugmakers believe COVID-19 may change the ways of working for good, even after the pandemic eases. (Getty Images) As COVID-19 vaccines are rolling out in different parts of the world, perhaps it’s finally time to talk about life after the pandemic. But biopharma companies believe it’s too early to put a specific timeline on turning that page now. Despite all the unknowns, though, one thing seems certain: How drugmakers conduct their business will change. After navigating the past few months, “one thing is clear to us: We will not return to the old ways of working ...

Dec 21, 2020 11:00am WuXi Biologics will pay Bayer €150 million to take charge at the company's drug product manufacturing plant in Wuppertal, Germany—one of two German plants WuXi picked up from the drugmaker this year. (Bayer) Shanghai's WuXi Biologics is ending the year how it started: with plans to take charge at a Bayer facility in Germany. The company's latest site acquisition follows deals for three U.S. facilities this year, part of WuXi Bio's gung-ho expansion efforts outside of China.  WuXi Bio is stumping up €150 million ($183.3 million) to take over Bayer's drug sub...